Member Info for Dalester

In theory yes, but there is a 180 day "grace period" that allows companies to move above the 1$ threshold...

There is a growing exodus from the UK to the US in search of finance liquidity.. the US markets are worth $53 trillion, the UK is £3trillion... the AIm market has halved in the numer of companies listed in recent years... whilst the plan is not crystal clear yet, its certain we will need more and more cash to move all our potential to market. Another dilution, if it comes to it, seems a reasonable price to pay for the opportunity to put the share price at many many times its current level. Given enough finance, the ability to go it alone becomes a credible option, and a big negotiation chip to put on the table during any partnering discussions.... The scientists have done their work, its time for the financial guys to show their worth now...

on the back of a *** packet, thats about £115 a share with 212m shares so about £23- £24 a share in scancell terms with roughly 5 times as many shares ? crikey!

melanoma patients run at about 2.1 vs pancreatic in the uk and the global theraputic market opportunity is about the sale ratio - £8.7bn to 3.6bn...

Or... they are under 1 or maybe several NDAs ...Either way something is brewing and given the length of " radio silence" , there must be a lot of due diligence and negotiation going on, its difficult to see any other reason for not shouting about current activity and results....

Ray, I hwve no real idea, but I guess its possible? I was actually wondering if some sort of deal with the new Glymab Theraputics entity between Genmab and Scancell would suit both parties, especially if the two Mabs we sold them are making good progress. Sacrificing some of the long term stage payments for enough to get scib through stage 3 would seem to be pragmatic at this point if the intention is to go it alone. Retaining say 40% of GT in exchange for a few hundred millions ( or hopefully more)at this stage might be a good deal for both companies...

Reminder...

The ProfoundBio Acquisition ($1.8 Billion): In spring 2024, Genmab acquired ProfoundBio for $1.8 billion to secure their experimental antibody-drug conjugate (ADC), rinatabart sesutecan (Rina-S), which targets solid tumors like ovarian cancer.

Reminder...

The ProfoundBio Acquisition ($1.8 Billion): In spring 2024, Genmab acquired ProfoundBio for $1.8 billion to secure their experimental antibody-drug conjugate (ADC), rinatabart sesutecan (Rina-S), which targets solid tumors like ovarian cancer.

But.. the opportunity of listing in the US is too good to resist given that AIM has lost half of its listings in the last few years, it isnt a growing, dynamic environment for investors (as opposed to traders). The funding problems faced by business kill off the entrepreneurial spirit , as do dimwit , revolving doors Ministers, sclerotic civil servants and (apparently, in our case) entrenched medical oversight committees. By comparison the US can-do attitudes simply exacerbate the can't- do attitudes of a country in what feels like terminal decline. I feel Phil's frustration. Welcome to the UK where building something as relatively simple as a railway becomes the most expensive 140 miles of railway ever not built.

Didn't Zak Mir reckon that 27p would be by the end of the month? If people bought in on his advice and saw 27p today, they might have bailed out without realising what else was on the horizon? Still, an up day and good volume, onwards and upwards!

Didn't Berry Head sing that song about Bangkok from Chess?

According to Google..."Chinese companies are heavily involved in the development of Monoclonal Antibodies (mAbs) and have become a major force in global biopharma innovation. As of 2025–2026, China is responsible for a significant portion of global oncology drug licensing deals, particularly for mAbs and Antibody-Drug Conjugates" so I guess there might be quite a lot of Chinese interest in Avidimab...If there are NDAs in place regarding SCIB, it would make sense for the BDM to be concentrating on other aspects of the portfolio...it pays to advertise....!

There is some interesting language in the RNS.. The new guy is clearly a deal- maker and will apparently be "interim" CFO" indicating that they will either bring in a new CFO at a later date or perhaps that they don't anticipate needing a new one? Either option indicates that Sath's resignation was unexpected and the position needed to be filled quickly, maybe someone noticed that he seemed to be doing a pretty good job here and made him an offer he couldn't turn down.

The new appointment also adds an expertise in deal- making, that has not been in the building hitherto outside of Phil. It also feels like we are heading for an inflection point of some sort.

More here, dont think we are involved.. but it looks like this treatment might need some help.....

https://www.massgeneral.org/news/press-release/clinical-trial-results-show-dramatic-regression-of-glioblastoma-after-next-generation-car-t-therapy#:~:text=The%20patients%20tolerated%20the%20infusions,in%20the%20hospital%20before%20discharge.

Https://www.aan.com/about-the-aan/advertise-aan

Just email and ask for a rate card.......

Clearing the decks,.... removing ammunition from the Doubting Thomases ahead of Modi news... maybe they will tell us about the reasons for putting the Glycan Mabs in their own little box too...

I thought this bit was interesting from Fingerpaint..

"An internal code name or trial designation cannot garner the attention of physicians and patients the way a more robust brand can. "

All those Mabs with SC numbers .. getting new names that reflect what they are aimed at? Modi? Scib?

Things getting interesting ..... They are gearing up for something....

Just popped into the "other side" to see whats going on and it seems to have got extremely personal ... whoever is running the chat boards over there needs to get to grips now, its gone way beyond " banter "... its now descended into defamation...

Is there any reason that the Glymab company couldnt be floated on Nasdaq rather than sold or partly sold? My understanding is the Pharma IPOs in the US are likely to attract $100s of millions of investment.

https://www.thebusinessresearchcompany.com/market-insights/monoclonal-antibodies-mabs-market-overview-2025

"To replace the troubled mRNA programs, we’re prioritizing the development of safer, broader vaccine strategies, like whole-virus vaccines and novel platforms that don’t collapse when viruses mutate,” Kennedy said in the video."

Genmab to acquire ProfoundBio for USD 1.8 billion in cash

Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate (ADC) technology platforms

Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumors

So they paid about $600m for each Mab.....$1.8bn or about £1.3bn in old money ..... tick tock....?